Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multikinase Treatment of Glioblastoma, Evaluating the Rationale for Regorafenib

  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Meléndez, Bárbara
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Sanz, Carolina
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Arpí-Llucia, Oriol
  • Gut, Marta|||0000-0002-4063-7159
  • Esteve, Anna|||0000-0002-1962-971X
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Parra, Genis
  • Carrato, Cristina|||0000-0002-1953-8287
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Pineda, Estela|||0000-0003-2128-747X
  • Alameda, Francesc|||0000-0002-7302-6901
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Estival, Anna|||0000-0002-2788-9159
  • Balañá, Carmen|||0000-0003-0771-0390
For a targeted drug to be effective, the target must be present. To determine if this condition was met for regorafenib in glioblastoma, we analyzed 46 genes encoding protein kinases (PKs) inhibited by regorafenib in preclinical studies. We further focused on a subset of 18 genes encoding PKs inhibited by regorafenib at clinically achievable concentrations, which-together with the anti-angiogenetic activity of regorafenib-constituted the rationale for the REGOMA and AGILE trials. Oncogenic/likely oncogenic mutations, gene amplification, fusions, and/or gene overexpression indicated a potential regorafenib target. Thirty-four (33%) and twenty-six (25.2%) patients harbored at least one such alteration in the 46- and 18-gene sets, respectively. However, these results may overestimate the effectiveness of regorafenib due to its difficulty in penetrating the blood-brain barrier to reach the target. Future use of multi-target drugs should be guided by a thorough understanding of target presence and the drug's ability to reach the target. We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites and performed a functional enrichment analysis to assess their implications in angiogenesis. We analyzed regorafenib's binding inhibitory activity and target affinity for these 46 PKs and focused on a subset of 18 genes inhibited by regorafenib at clinically achievable concentrations and on 19 genes involved in angiogenesis. Putative oncogenic alterations were defined as oncogenic/likely oncogenic mutations, oncogenic fusions, CNVs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Alameda, Francesc|||0000-0002-7302-6901
  • Carrato, Cristina|||0000-0002-1953-8287
  • Pineda, Estela|||0000-0003-2128-747X
  • Arpí Lluciá, Oriol|||0000-0002-5578-2092
  • Martinez-García, Maria
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Gut, Marta|||0000-0002-4063-7159
  • Del Barco Berrón, Sonia|||0000-0002-4951-6871
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Dabad, Marc|||0000-0002-6094-747X
  • Mesia, Carlos
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Vidal, Noemí|||0000-0002-2852-6667
  • Aldecoa, Iban|||0000-0001-5774-7453
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Balañá, Carmen|||0000-0003-0771-0390
RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in tumor samples from 139 newly diagnosed glioblastoma patients to identify in-frame fusions with predictable oncogenic potential. Among 61 samples with fusions, there were 103 different fusions, involving 167 different genes, including 20 known oncogenes or tumor suppressor genes (TSGs), 16 associated with cancer but not oncogenes or TSGs, and 32 not associated with cancer but previously shown to be involved in fusions in gliomas. After selecting in-frame fusions able to produce a protein product and running Oncofuse, we identified 30 fusions with predictable oncogenic potential and classified them into four non-overlapping categories: six previously described in cancer; six involving an oncogene or TSG; four predicted by Oncofuse to have oncogenic potential; and 14 other in-frame fusions. Only 24 patients harbored one or more of these 30 fusions, and only two fusions were present in more than one patient: FGFR3::TACC3 and EGFR::SEPTIN14. This in silico study provides a good starting point for the identification of gene fusions with functional consequences in the pathogenesis or treatment of glioblastoma.